公开(公告)号：US08173657B2

公开(公告)日：2012-05-08

申请号：US12294233

申请日：2007-03-23

Applicant: James Sutton ,  Feng Xu ,  Nicholas Valiante ,  Jiong Lan

Inventor： James Sutton ,  Feng Xu ,  Nicholas Valiante ,  Jiong Lan

IPC: A61K31/50 ,  A61K39/02 ,  A61K39/12 ,  A61K39/00 ,  C07D471/00 ,  C07D487/00

CPC classification number: A61K31/4985 ,  A61K39/21 ,  A61K39/39 ,  C07D487/04

Abstract: The invention provides novel compositions comprising imidazoquinoxaline compounds of formula (I) and analogs thereof. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an) other agent(s).

Abstract translation: 本发明提供了包含式（I）的咪唑并喹喔啉化合物及其类似物的新型组合物。 还提供了以有效量施用组合物以增强受试者的免疫应答的方法。 进一步提供了组合物与（一种或多种）其它试剂组合施用的新组合物和方法。

公开(公告)号：US20090232844A1

公开(公告)日：2009-09-17

申请号：US12294237

申请日：2007-03-23

Applicant: James Sutton ,  Nicholas Valiante

Inventor： James Sutton ,  Nicholas Valiante

IPC: A61K39/145 ,  C07D471/04 ,  A61K31/437 ,  A61K31/4375 ,  C07D471/14 ,  A61P31/12 ,  A61P31/04 ,  A61K39/00 ,  A61K39/02 ,  A61K39/12

CPC classification number: C07D471/14 ,  C07D471/04

Abstract: The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).

Abstract translation: 本发明提供包含咪唑并吡啶化合物的新型组合物。 还提供了以有效量施用组合物以增强受试者的免疫应答的方法。 进一步提供了组合物与（一种或多种）其它试剂组合施用的新组合物和方法。

公开(公告)号：US08063063B2

公开(公告)日：2011-11-22

申请号：US12294237

申请日：2007-03-23

Applicant: James Sutton ,  Nicholas Valiante

Inventor： James Sutton ,  Nicholas Valiante

IPC: A01N43/42 ,  A61K31/44 ,  C07D471/02 ,  C07D491/02 ,  C07D498/02 ,  C07D513/02

CPC classification number: C07D471/14 ,  C07D471/04

Abstract: The invention provides novel compositions comprising Imidazopyridine compounds. Also provided are methods of administering the compositions in an effective amount to enhance the immune response of a subject. Further provided are novel compositions and methods of administering the compositions in combination with (an)other agent(s).

Abstract translation: 本发明提供包含咪唑并吡啶化合物的新型组合物。 还提供了以有效量施用组合物以增强受试者的免疫应答的方法。 进一步提供了组合物与（一种或多种）其它试剂组合施用的新组合物和方法。

公开(公告)号：US20130303507A1

公开(公告)日：2013-11-14

申请号：US13981283

申请日：2012-01-20

Applicant: William R. Antonios-McCrea ,  Paul A. Barsanti ,  Cheng Hu ,  Xianming Jin ,  Eric Martin ,  Yue Pan ,  Xiaodong Lin ,  Keith B. Pfister ,  Paul A. Renhowe ,  Martin Sendzik ,  James Sutton ,  Lifeng Wan

Inventor： William R. Antonios-McCrea ,  Paul A. Barsanti ,  Cheng Hu ,  Xianming Jin ,  Eric Martin ,  Yue Pan ,  Xiaodong Lin ,  Keith B. Pfister ,  Paul A. Renhowe ,  Martin Sendzik ,  James Sutton ,  Lifeng Wan

IPC: C07D401/14 ,  C07D401/04 ,  C07D491/107 ,  C07D409/14 ,  C07D413/14 ,  C07D487/04 ,  C07D213/74 ,  C07D405/14

CPC classification number: C07D401/14 ,  C07D213/74 ,  C07D401/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D487/04 ,  C07D491/107

Abstract: The present invention provides a compound of formula (II): where R1 is a substituted alkyl, heterocyclic, or cycloalkyl, group, and pharmaceutically acceptable salts, enantiomers, stereoisomers, rotamers, tautomers, diastereomers, or racemates thereof, and pharmaceutical compositions comprising these compounds. Also provided are methods of using these compounds to treat a disease or condition mediated by CDK9, such as cancers and other conditions described herein.

Abstract translation: 本发明提供式（II）化合物：其中R 1是取代的烷基，杂环或环烷基，基团及其药学上可接受的盐，对映异构体，立体异构体，旋转异构体，互变异构体，非对映异构体或外消旋物，以及包含它们的药物组合物 化合物。 还提供了使用这些化合物治疗由CDK9介导的疾病或病症的方法，例如本文所述的癌症和其它病症。

公开(公告)号：US20100130490A1

公开(公告)日：2010-05-27

申请号：US12451326

申请日：2008-05-20

Applicant: Simon C. Ng ,  Keith B. Pfister ,  Martin Sendzik ,  James Sutton ,  Allan S. Wagman ,  Marion Wiesmann

Inventor： Simon C. Ng ,  Keith B. Pfister ,  Martin Sendzik ,  James Sutton ,  Allan S. Wagman ,  Marion Wiesmann

IPC: A61K31/428 ,  C12N5/00 ,  A61K31/5377 ,  A61K31/501 ,  A61K31/497 ,  A61K31/519 ,  A61K31/517 ,  A61K31/506 ,  A61K31/4439 ,  C07D417/12 ,  C07D487/04 ,  C07D417/14 ,  C07D277/82 ,  A61P35/00 ,  A61P19/10 ,  A61P19/02 ,  A61P13/00

CPC classification number: C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D495/04

Abstract: Benzoxazole and benzothiazole compounds and their oxides, esters, prodrugs, solvates, and pharmaceutically acceptable salts thereof are disclosed. Compositions of the compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier, and uses of the compounds, either alone or in combination with at least one additional therapeutic agent are also disclosed. The embodiments are useful for inhibiting cellular proliferation, inhibiting the growth and/or metathesis of tumors, treating or preventing cancer, treating or preventing degenerating bone diseases such as rheumatoid arthritis, and/or inhibiting molecules such as CSF 1R.

Abstract translation: 公开了苯并恶唑和苯并噻唑化合物及其氧化物，酯，前药，溶剂合物及其药学上可接受的盐。 还公开了单独或与至少一种另外的治疗剂组合的化合物与药学上可接受的载体的组合，以及化合物单独或与至少一种另外的治疗剂组合的用途。 这些实施方案可用于抑制细胞增殖，抑制肿瘤的生长和/或复分解，治疗或预防癌症，治疗或预防退行性骨疾病如类风湿性关节炎和/或抑制分子如CSF 1R。

公开(公告)号：US20070004677A1

公开(公告)日：2007-01-04

申请号：US11474900

申请日：2006-06-26

Applicant: Hannguang Chao ,  R. Lawrence ,  Rejean Ruel ,  James Sutton

Inventor： Hannguang Chao ,  R. Lawrence ,  Rejean Ruel ,  James Sutton

IPC: C07F5/02 ,  A61K31/69 ,  C07D417/02 ,  C07D409/02 ,  C07D401/02 ,  C07D213/22

CPC classification number: C07D213/75 ,  C07D213/76 ,  C07D405/12 ,  C07D409/12 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention provides novel urea mimics and analogues of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, W, and R6 are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.

Abstract translation: 本发明提供新颖的脲模拟物和式（I）的类似物：或其立体异构体，互变异构体，药学上可接受的盐或溶剂化物形式，其中变量A，B，W和R 6为 本文定义。 这些化合物是可用作药物的人P2Y 1受体的选择性抑制剂。

公开(公告)号：US20060293281A1

公开(公告)日：2006-12-28

申请号：US11474888

申请日：2006-06-26

Applicant: Jennifer Qiao ,  Tammy Wang ,  James Sutton ,  Timur Gungor

Inventor： Jennifer Qiao ,  Tammy Wang ,  James Sutton ,  Timur Gungor

IPC: A61K31/695 ,  C07F7/02 ,  A61K31/554 ,  A61K31/551 ,  A61K31/538 ,  C07D417/02 ,  C07D403/02 ,  C07D413/02 ,  A61K31/4439 ,  A61K31/5415 ,  A61K31/5513 ,  A61K31/553

CPC classification number: C07D471/10 ,  C07D401/04 ,  C07D401/12 ,  C07D417/12 ,  C07D417/14

Abstract: The present invention provides novel ureas containing N-aryl or N-heteroaryl substituted heterocycles of Formula (I): or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, B, D and W are as defined herein. These compounds are selective inhibitors of the human P2Y1 receptor which can be used as medicaments.

Abstract translation: 本发明提供了包含式（I）的N-芳基或N-杂芳基取代的杂环的新型脲：或其立体异构体，互变异构体，药学上可接受的盐或溶剂化物形式，其中变量A，B，D和W如本文所定义 。 这些化合物是可用作药物的人P2Y 1受体的选择性抑制剂。

公开(公告)号：US20060205489A1

公开(公告)日：2006-09-14

申请号：US11275301

申请日：2005-12-22

Applicant: Jerome Carpenter ,  Faith LeBrun ,  Steven Lee ,  James Sutton ,  Craig Sylla

Inventor： Jerome Carpenter ,  Faith LeBrun ,  Steven Lee ,  James Sutton ,  Craig Sylla

IPC: A63F9/24

CPC classification number: G07F17/32 ,  G07F17/3206 ,  G07F17/3237 ,  G07F17/3239 ,  G07F17/3241

Abstract: One embodiment of the invention includes a method of monitoring behavior of a group of casino game players. The method includes identifying a group of casino game players for profiling; profiling the game players based upon their actions in a gaming establishment; and providing options for game play and service to the game players based upon their profile.

Abstract translation: 本发明的一个实施例包括监视一组赌场游戏玩家的行为的方法。 该方法包括识别用于轮廓分析的一组赌场游戏玩家; 根据游戏机构的行为来分析游戏玩家; 并基于他们的个人资料为游戏玩家提供游戏和服务的选项。

公开(公告)号：US20060200680A1

公开(公告)日：2006-09-07

申请号：US09672602

申请日：2001-02-26

Applicant: Carl Ellison ,  Roger Golliver ,  Howard Herbert ,  Derrick Lin ,  Francis McKeen ,  Gilbert Neiger ,  Ken Reneris ,  James Sutton ,  Shreekant Thakkar ,  Millind Mittal

Inventor： Carl Ellison ,  Roger Golliver ,  Howard Herbert ,  Derrick Lin ,  Francis McKeen ,  Gilbert Neiger ,  Ken Reneris ,  James Sutton ,  Shreekant Thakkar ,  Millind Mittal

IPC: G06F12/14

CPC classification number: G06F12/1491 ,  G06F21/57 ,  G06F2221/2105

Abstract: In an embodiment of the present invention, a technique is provided for remote attestation. An interface maps a device via a bus to an address space of a chipset in a secure environment for an isolated execution mode. The secure environment is associated with an isolated memory area accessible by at least one processor. The at least one processor operates in one of a normal execution mode and the isolated execution mode. A communication storage corresponding to the address space allows the device to exchange security information with the at least one processor in the isolated execution mode in a remote attestation.

Abstract translation: 在本发明的实施例中，提供了用于远程证明的技术。 接口将设备通过总线映射到安全环境中的芯片组的地址空间，用于隔离执行模式。 安全环境与由至少一个处理器可访问的隔离存储器区域相关联。 所述至少一个处理器以正常执行模式和隔离执行模式之一进行操作。 对应于地址空间的通信存储器允许设备在远程证明中以隔离执行模式与至少一个处理器交换安全信息。

公开(公告)号：US20060026525A1

公开(公告)日：2006-02-02

申请号：US10900875

申请日：2004-07-28

Applicant: Stephen A. Fischer ,  Dion Rodgers ,  James Sutton

Inventor： Stephen A. Fischer ,  Dion Rodgers ,  James Sutton

IPC: G06F17/00

CPC classification number: G06F9/30101 ,  G06F9/30181 ,  G06F21/629

Abstract: A processor includes a feature control unit to enable or disable one or more processor features individually in response to a user selectable setting. The feature control unit is adapted to disable the processor feature(s) if the user setting has not been updated in accordance with an input regardless of the value of the user setting prior to the update and to enable or disable the processor feature(s) in accordance with the updated user setting after it has been updated. The feature control unit may also include a lock unit to prevent changes to the updated user setting and a software feature selection unit to enable or disable processor features in response to a software feature selection setting and, optionally, only enable or disable processor features whose corresponding updated user setting is user enabled. The feature control unit may also include mechanisms to detect illegal feature selection conditions.

Abstract translation: 处理器包括特征控制单元，以响应于用户可选择的设置来单独启用或禁用一个或多个处理器特征。 如果没有根据输入更新用户设置而不考虑更新之前的用户设置的值，并且启用或禁用处理器特征，则特征控制单元适于禁用处理器特征， 根据更新后的用户设置进行更新。 特征控制单元还可以包括用于防止更新的用户设置的改变的锁定单元和软件特征选择单元以响应于软件特征选择设置来启用或禁用处理器特征，并且可选地，仅启用或禁用其相应的处理器特征 更新的用户设置是用户启用的。 特征控制单元还可以包括检测非法特征选择条件的机制。